Logo image of CGC

CANOPY GROWTH CORP (CGC) Stock Fundamental Analysis

NASDAQ:CGC - Nasdaq - CA1380357048 - Common Stock - Currency: USD

1.77  +0.13 (+7.93%)

After market: 1.7599 -0.01 (-0.57%)

Fundamental Rating

2

Overall CGC gets a fundamental rating of 2 out of 10. We evaluated CGC against 198 industry peers in the Pharmaceuticals industry. While CGC seems to be doing ok healthwise, there are quite some concerns on its profitability. CGC has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CGC had negative earnings in the past year.
In the past year CGC has reported a negative cash flow from operations.
CGC had negative earnings in each of the past 5 years.
In the past 5 years CGC always reported negative operating cash flow.
CGC Yearly Net Income VS EBIT VS OCF VS FCFCGC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1B -2B -3B

1.2 Ratios

CGC has a Return On Assets of -40.34%. This is comparable to the rest of the industry: CGC outperforms 45.45% of its industry peers.
CGC's Return On Equity of -79.41% is in line compared to the rest of the industry. CGC outperforms 44.95% of its industry peers.
Industry RankSector Rank
ROA -40.34%
ROE -79.41%
ROIC N/A
ROA(3y)-63.49%
ROA(5y)-47.06%
ROE(3y)-181.56%
ROE(5y)-123.98%
ROIC(3y)N/A
ROIC(5y)N/A
CGC Yearly ROA, ROE, ROICCGC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

CGC has a Gross Margin (30.40%) which is comparable to the rest of the industry.
CGC's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for CGC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 30.4%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y29.93%
GM growth 5Y16.63%
CGC Yearly Profit, Operating, Gross MarginsCGC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

More info and screens

4

2. Health

2.1 Basic Checks

CGC does not have a ROIC to compare to the WACC, probably because it is not profitable.
CGC has less shares outstanding than it did 1 year ago.
CGC has less shares outstanding than it did 5 years ago.
The debt/assets ratio for CGC has been reduced compared to a year ago.
CGC Yearly Shares OutstandingCGC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M
CGC Yearly Total Debt VS Total AssetsCGC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

2.2 Solvency

Based on the Altman-Z score of -9.69, we must say that CGC is in the distress zone and has some risk of bankruptcy.
CGC's Altman-Z score of -9.69 is on the low side compared to the rest of the industry. CGC is outperformed by 70.71% of its industry peers.
A Debt/Equity ratio of 0.79 indicates that CGC is somewhat dependend on debt financing.
CGC has a worse Debt to Equity ratio (0.79) than 68.18% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.79
Debt/FCF N/A
Altman-Z -9.69
ROIC/WACCN/A
WACC10.13%
CGC Yearly LT Debt VS Equity VS FCFCGC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B 6B

2.3 Liquidity

A Current Ratio of 3.52 indicates that CGC has no problem at all paying its short term obligations.
CGC has a better Current ratio (3.52) than 61.62% of its industry peers.
CGC has a Quick Ratio of 2.58. This indicates that CGC is financially healthy and has no problem in meeting its short term obligations.
CGC has a Quick ratio of 2.58. This is comparable to the rest of the industry: CGC outperforms 53.03% of its industry peers.
Industry RankSector Rank
Current Ratio 3.52
Quick Ratio 2.58
CGC Yearly Current Assets VS Current LiabilitesCGC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 74.44% over the past year.
Looking at the last year, CGC shows a decrease in Revenue. The Revenue has decreased by -7.16% in the last year.
CGC shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.60% yearly.
EPS 1Y (TTM)74.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.63%
Revenue 1Y (TTM)-7.16%
Revenue growth 3Y-18.39%
Revenue growth 5Y5.6%
Sales Q2Q%-4.77%

3.2 Future

CGC is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.03% yearly.
The Revenue is expected to grow by 1.96% on average over the next years.
EPS Next Y51.93%
EPS Next 2Y38.97%
EPS Next 3Y24.86%
EPS Next 5Y14.03%
Revenue Next Year-16.49%
Revenue Next 2Y-5.42%
Revenue Next 3Y-1.49%
Revenue Next 5Y1.96%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
CGC Yearly Revenue VS EstimatesCGC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M 400M 500M
CGC Yearly EPS VS EstimatesCGC Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -20 -40 -60

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CGC. In the last year negative earnings were reported.
Also next year CGC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CGC Price Earnings VS Forward Price EarningsCGC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CGC Per share dataCGC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 -3

4.3 Compensation for Growth

CGC's earnings are expected to grow with 24.86% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.97%
EPS Next 3Y24.86%

More info and screens

0

5. Dividend

5.1 Amount

CGC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CANOPY GROWTH CORP

NASDAQ:CGC (5/20/2025, 8:00:00 PM)

After market: 1.7599 -0.01 (-0.57%)

1.77

+0.13 (+7.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-07 2025-02-07/bmo
Earnings (Next)05-30 2025-05-30/amc
Inst Owners6.95%
Inst Owner Change67.53%
Ins Owners0.06%
Ins Owner Change2.29%
Market Cap371.93M
Analysts46.67
Price Target2.61 (47.46%)
Short Float %8.44%
Short Ratio2.22
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-166.14%
Min EPS beat(2)-231.12%
Max EPS beat(2)-101.15%
EPS beat(4)0
Avg EPS beat(4)-174.49%
Min EPS beat(4)-240.27%
Max EPS beat(4)-101.15%
EPS beat(8)1
Avg EPS beat(8)-220.62%
EPS beat(12)1
Avg EPS beat(12)-210.52%
EPS beat(16)4
Avg EPS beat(16)-164.13%
Revenue beat(2)1
Avg Revenue beat(2)2.88%
Min Revenue beat(2)-0.3%
Max Revenue beat(2)6.06%
Revenue beat(4)2
Avg Revenue beat(4)2.6%
Min Revenue beat(4)-8.11%
Max Revenue beat(4)12.74%
Revenue beat(8)4
Avg Revenue beat(8)2.36%
Revenue beat(12)5
Avg Revenue beat(12)-2.05%
Revenue beat(16)6
Avg Revenue beat(16)-2.85%
PT rev (1m)-0.61%
PT rev (3m)-38.7%
EPS NQ rev (1m)0%
EPS NQ rev (3m)9.57%
EPS NY rev (1m)0%
EPS NY rev (3m)-19.68%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.79%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.77%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.87
P/FCF N/A
P/OCF N/A
P/B 0.88
P/tB 1.13
EV/EBITDA N/A
EPS(TTM)-3.74
EYN/A
EPS(NY)-0.43
Fwd EYN/A
FCF(TTM)-0.56
FCFYN/A
OCF(TTM)-0.53
OCFYN/A
SpS0.94
BVpS2.02
TBVpS1.56
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -40.34%
ROE -79.41%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 30.4%
FCFM N/A
ROA(3y)-63.49%
ROA(5y)-47.06%
ROE(3y)-181.56%
ROE(5y)-123.98%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y29.93%
GM growth 5Y16.63%
F-Score6
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity 0.79
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 19.12%
Cap/Sales 2.97%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.52
Quick Ratio 2.58
Altman-Z -9.69
F-Score6
WACC10.13%
ROIC/WACCN/A
Cap/Depr(3y)20.68%
Cap/Depr(5y)155.29%
Cap/Sales(3y)4.46%
Cap/Sales(5y)45.25%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)74.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.63%
EPS Next Y51.93%
EPS Next 2Y38.97%
EPS Next 3Y24.86%
EPS Next 5Y14.03%
Revenue 1Y (TTM)-7.16%
Revenue growth 3Y-18.39%
Revenue growth 5Y5.6%
Sales Q2Q%-4.77%
Revenue Next Year-16.49%
Revenue Next 2Y-5.42%
Revenue Next 3Y-1.49%
Revenue Next 5Y1.96%
EBIT growth 1Y64.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year92.97%
EBIT Next 3Y26.49%
EBIT Next 5Y16.65%
FCF growth 1Y70.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y71.6%
OCF growth 3YN/A
OCF growth 5YN/A